Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -99.83% is 18% below its 5-year average of -84.80%, near the high end of its 5-year range (-913.20%–-46.41%).
As of the fiscal period ended Tuesday, June 30, 2026. 31.94% below its 12-month average of -75.66%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -99.83%.
RETURN ON EQUITY (ROE)
-99.83%
RETURN ON EQUITY (ROE) AVG TTM
-75.66%
RETURN ON EQUITY (ROE) AVG 3Y
-94.83%
RETURN ON EQUITY (ROE) AVG 5Y
-84.80%
RETURN ON EQUITY (ROE) AVG 10Y
-61.00%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-31.94%
CURRENT VS 3Y AVG
-5.28%
CURRENT VS 5Y AVG
-17.73%
CURRENT VS 10Y AVG
-63.65%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 392 covered companies
CURRENT VS SECTOR MEDIAN
-177.26%
vs the sector median at left
Crescent Biopharma, Inc.
Market Cap
$517.79M
Return on Equity (ROE)
-99.83%
TTM Avg
-75.66%
3Y Avg
-94.83%
5Y Avg
-84.80%
Market Cap
$517.73M
Return on Equity (ROE)
-37.94%
TTM Avg
-63.13%
3Y Avg
-60.30%
5Y Avg
-47.34%
Market Cap
$519.25M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
Market Cap
$491.93M
Return on Equity (ROE)
N/A
TTM Avg
-344.79%
3Y Avg
-198.42%
5Y Avg
-104.57%
Market Cap
$491.55M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$547.86M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$487.30M
Return on Equity (ROE)
-8.21%
TTM Avg
-32.76%
3Y Avg
-79.80%
5Y Avg
-71.61%
Market Cap
$551.09M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$481.33M
Return on Equity (ROE)
1.65%
TTM Avg
-27.02%
3Y Avg
-39.92%
5Y Avg
-33.78%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $517.79M | -99.83% | -75.66% | -94.83% | -84.80% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -37.94% | -63.13% | -60.30% | -47.34% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -19.35% | -58.07% | -51.86% | -46.32% |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | -344.79% | -198.42% | -104.57% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -6.60% | -10.82% | -11.36% | -7.59% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.44% | -17.98% | 71.24% | -6.51% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | -8.21% | -32.76% | -79.80% | -71.61% |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | -17.44% | -97.25% | -87.77% | -77.06% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 1.65% | -27.02% | -39.92% | -33.78% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -24.02% | -22.16% | -34.88% | -37.32% |
ROE
-99.8%
ROA
-89.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -99.83% |
| 2026-03-31 | -88.16% |
| 2025-12-31 | -75.83% |
| 2025-09-30 | -68.08% |
| 2025-06-30 | -46.41% |
| 2024-12-31 | -913.20% |
| 2024-09-30 | -349.28% |
| 2024-06-30 | -194.96% |
| 2024-03-31 | -128.94% |
| 2023-12-31 | -96.06% |
| 2023-09-30 | -81.78% |
| 2023-06-30 | -68.22% |
| 2023-03-31 | -68.18% |
| 2022-12-31 | -108.76% |
| 2022-09-30 | -111.95% |
| 2022-06-30 | -112.47% |
| 2022-03-31 | -93.79% |
| 2021-12-31 | -77.73% |
| 2021-09-30 | -63.76% |
| 2021-06-30 | -51.62% |
| 2021-03-31 | -46.07% |
| 2020-12-31 | -39.80% |
| 2020-09-30 | -36.30% |
| 2020-06-30 | -34.11% |
| 2020-03-31 | -34.66% |
| 2019-12-31 | -37.54% |
| 2019-09-30 | -34.16% |
| 2019-06-30 | -31.02% |
| 2019-03-31 | -26.37% |
| 2018-12-31 | -23.49% |
| 2018-09-30 | -20.00% |
| 2018-06-30 | -17.54% |
| 2018-03-31 | -15.49% |
| 2017-12-31 | -27.80% |
| 2017-09-30 | -29.80% |
| 2017-06-30 | -27.94% |
| 2017-03-31 | -100.94% |
| 2016-12-31 | -90.11% |
| 2016-09-30 | -77.51% |
| 2016-06-30 | -64.81% |
| 2016-03-31 | -38.01% |
| 2015-12-31 | -31.55% |
| 2015-09-30 | -23.16% |
| 2015-06-30 | -19.43% |
| 2015-03-31 | -29.60% |
| 2014-12-31 | -21.89% |
| 2014-09-30 | -13.16% |
| 2014-06-30 | -7.32% |
| 2014-03-31 | -29.21% |
| 2013-12-31 | -364.78% |
| 2013-09-30 | -93.63% |
| 2013-06-30 | -16.19% |
